Biopurification Process Reaches Patent Milestone
Biopurification Process Reaches Patent Milestone
A Notice of Approval from the US Patent and Trademark Office moves GTC Biotherapeutics (Framingham, MA) one step closer to receiving a patent for its biopurification process based on tangential flow filtration (TFF). Specifically, the company’s approach would speed the recovery of recombinant therapeutic proteins, endogenous proteins, fusion proteins, protein fragments, and antibodies from feedstreams of transgenic mammalian milk.
In the patent application titled “Methods of tangential flow filtration and an apparatus therefore,” GTC researchers implement TFF technology “to clarify, concentrate, and fractionate the desired recombinant protein or other molecule of interest from the native components of milk or contaminants thereof. The resulting clarified bulk intermediate is a suitable feed material for traditional purification techniques such as chromatography which are used downstream from the TFF process to bring the product to its final formulation and purity.”
Company researchers produce therapeutic proteins in animal milk using transgenic technology, in which a gene that expresses a specific protein is coupled with a particular milk-protein promoter gene. The system is then incorporated into an animal's genome, and the protein is expressed during the animal's lactation. GTC claims this approach “enables the production of therapeutic proteins that are difficult to express in traditional production methods.”
–Maribel Rios
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Cooperating With Our Customers Across the US
May 13th 2025Highlighting the importance for our clients to prepurchase multi-year maintenance contracts, in order to avoid their machines breaking or stopping to work suddenly and unexpectedly, to minimize the risk of interrupted production and emergency maintenance costs.
